Skip to main content
Prelude Therapeutics Inc logo

Prelude Therapeutics Inc — Investor Relations & Filings

Ticker · PRLD ISIN · US74065P1012 US Manufacturing
Open in API
Filings indexed 356 across all filing types
Latest filing 2023-06-21 Declaration of Voting R…
Country US United States of America
Listing US PRLD

About Prelude Therapeutics Inc

https://preludetx.com/

Prelude Therapeutics is a clinical-stage precision oncology company focused on discovering and developing innovative medicines for cancer patients with high unmet needs. The company's pipeline features small molecule therapies and leverages expertise in targeted protein degradation. Key development programs include highly selective KAT6A degraders for solid tumors, such as ER+ breast cancer, and mutant-selective JAK2V617F JH2 inhibitors for myeloproliferative neoplasms. Prelude is also advancing next-generation degrader antibody conjugates (DACs) with novel payloads. The company's science-driven approach targets critical cancer cell pathways to create potentially transformative treatments.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filing by Prelude Therapeutics Incorporated reporting the results of its 2023 Annual Meeting of Stockholders. It specifically details the voting outcomes for the election of directors, the ratification of the independent accounting firm, and an amendment to the certificate of incorporation. According to the filing definitions, this is a Declaration of Voting Results & Voting Rights Announcement (DVA).
2023-06-21 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 1, 2023, for Prelude Therapeutics Incorporated. The key content is the disclosure of investor presentation materials prepared by the company, referenced as Exhibit 99.1. The text explicitly states that the materials are intended for use in investor presentations and are attached as an exhibit. The document is relatively short (3569 characters) and primarily serves to furnish the investor presentation rather than being the presentation itself or a detailed financial report. According to the classification rules, such a filing that provides presentation materials for investors is best classified as an Investor Presentation (IP).
2023-06-01 English
PRIMARY DOCUMENT
Director's Dealing
2023-05-26 English
PRIMARY DOCUMENT
Director's Dealing
2023-05-25 English
PRIMARY DOCUMENT
Director's Dealing
2023-05-25 English
PRIMARY DOCUMENT
Director's Dealing
2023-05-25 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.